Waters Corporation (WAT) has recently garnered attention from analysts, with Doug Schenkel of UBS upgrading the stock to a “Buy” on September 9, 2026. This recommendation comes with a price target of $490, representing a notable upside potential from its current trading price of $402.91. For investors keeping a close eye on the life sciences sector, this rating could signal a promising opportunity, especially in light of the company’s recent performance and future outlook.
Recent Price Action
In recent trading sessions, Waters Corporation’s stock has displayed a slight upward trend, closing the latest session up 1.01%, or $4.13, at $402.91. The stock remains well away from its 52-week high of $424.96, showing a decline of 22.05% from that peak, yet still comfortably above its 52-week low of $385.54, which highlights its resilience in a fluctuating market. The average trading volume over the past three months has been approximately 824,801 shares, though recent activity saw volumes dip to 295,838 shares, suggesting a phase of cautious investor sentiment or consolidation. With a market capitalization of about $30.44 billion and a beta of 1.194, WAT’s stock has exhibited moderate volatility, a characteristic that investors should consider when evaluating their potential risk exposure.
[chart type=’price’ value=’WAT’]
Historical Performance
Over the past month, WAT has posted a modest 1.79% increase in its share price, reflecting a stable but cautious market environment. In the broader context, the stock has performed notably better over the last three months, registering a 14.73% return as market conditions improved and investor confidence grew. However, the 12-month performance reveals a different narrative, with a decline of 5.32%, indicating that the stock has faced headwinds over the longer term. With a weekly volatility of 2.81% and a monthly volatility of 2.13%, WAT’s movements reveal that the stock has been relatively dynamic; therefore, investors should remain vigilant as they assess its ongoing stability against macroeconomic factors.
[chart type=’performance’ value=’WAT’]
Earnings Analysis
In its latest earnings report, Waters Corporation disclosed earnings per share (EPS) of $3.05, outperforming analysts’ expectations, which had established a consensus estimate of $3.01. This positive surprise, which registers at approximately 1.33%, stands in contrast to the previous period’s figures, where it delivered an EPS of $2.70 against an estimate of $2.31, leading to a significantly higher surprise factor of 16.88%. This consistent ability to beat EPS estimates could signal strong operational efficiency and a favorable outlook for the company’s performance dynamics, suggesting a level of financial health that investors may find appealing.
[chart type=’income-bar-chart’ value=’WAT’]
Consensus Ratings
Currently, the consensus among analysts is buoyant, with a total of 12 ratings on WAT stock. Notably, 10 of these recommend a “Buy,” while 2 maintain a “Hold” rating. Encouragingly, there are no sell ratings on the stock, which strengthens the view that optimistic sentiment prevails among market watchers. The average price target stands at approximately $437.92, while the newly established price target from UBS—set at $490—suggests that analysts see ample room for appreciation, which may entice investors looking for growth.
[chart type=’analyst-ratings’ value=’WAT’]
Stock Grading or Fundamental View
According to the Stocks Telegraph grading system, Waters Corporation holds a grade of 46. This score, which synthesizes various financial and market indicators, reflects a company that is relatively stable but could have areas needing improvement. While the rating indicates that Waters possesses certain fundamental strengths, there may also be competitive pressures that could restrain its performance in the near term. As a company embedded within the life sciences arena, investors should weigh both its innovative capabilities and the external market pressures that could shape its trajectory.
[chart type=’st-cards’ value=’WAT’]
Conclusion
Waters Corporation presents a compelling opportunity for long-term growth investors, particularly those with a tolerance for moderate risk and an interest in the life sciences sector. The recent upgrade to a “Buy” along with a high price target indicates a consensus belief in the company’s potential, particularly given its strong quarterly earnings report relative to expectations. However, potential investors should be cautious of the stock’s recent volatile behavior and the broader market dynamics. While WAT may suit growth-oriented portfolios, it is essential to continually monitor market trends and company performance to mitigate risks associated with its historical underperformance over the past year. With a cautiously optimistic outlook, Waters Corporation remains a stock to watch in the rapidly evolving landscape of life sciences and technology.